Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction

Motoyuki Kohjima, Kenta Motomura, Toshimasa Koyanagi, Seiya Tada, Naoki Yamashita, Takeaki Sato, Syoji Nagase, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We investigated the safety and effectiveness of the dual oral therapy with Daclatasvir (DCV) and Asunaprevir (ASV) for patients with renal dysfunctioa This study enrolled 682 HCV genotype lb patients treated with DCV and ASV and included 83 patients with eGFR less than 50 m//min/1.73 m2, and 17 patients with eGFR less than 30 m//min/L73 m2. Serum creatinine and eGFR were not altered during the treatment and the rate of complications and viral response was similar between patients with renal dysfunction and patients without renal dysfunction. The treatment with DCV and ASV was well tolerated and safety enough even for the HCV patients with renal dysfunction and could be productive therapeutic option for aged patients that accounts many of patients with HCV genotype lb infection in Japan.

Original languageEnglish
Pages (from-to)142-145
Number of pages4
JournalActa Hepatologica Japonica
Volume57
Issue number3
DOIs
Publication statusPublished - Apr 8 2016

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction'. Together they form a unique fingerprint.

  • Cite this

    Kohjima, M., Motomura, K., Koyanagi, T., Tada, S., Yamashita, N., Sato, T., Nagase, S., Kato, M., Kotoh, K., & Nakamuta, M. (2016). Therapeutic safety and effectiveness of dual oral therapy with daclatasvir and asunaprevir for chronic HCV patients with renal dysfunction. Acta Hepatologica Japonica, 57(3), 142-145. https://doi.org/10.2957/kanzo.57.142